Kringle Pharma, Inc. AI Stock Analysis
Want to see JP:4884 full AI Analyst Report?
Kringle Pharma, Inc. (4884) AI Stock Analysis
Kringle Pharma, Inc.
(TSE/TYO:4884)
The overall score reflects a highly speculative profile heavily weighed down by fundamental weaknesses. Substantial cash burn and a lack of profitability overshadow the stock's recent strong technical momentum. Investors should carefully weigh the persistent operational risks against the prevailing bullish price trends.
Kringle Pharma, Inc. (4884) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 4.97B
- Dividend Yield
- ―
- Average Volume (3M)
- 277.57K
- Price to Earnings (P/E)
- -4.7
- Beta (1Y)
- 0.43
- Revenue Growth
- 513.34%
- EPS Growth
- 20.92%
- Country
- Japan
- Employees
- 17
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Kringle Pharma, Inc. Business Overview & Revenue Model
Company Description
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious med...
Kringle Pharma, Inc. Financial Statement Overview
Summary
The company exhibits significant fundamental risks characterized by widening losses, zero gross profit, and severe cash burn. While its zero-debt capital structure provides a baseline of stability, eroding equity and contracting revenue severely limit financial health.
Income Statement
15Very NegativeBalance Sheet
62PositiveCash Flow
10Very Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 341.47M | 72.22M | 80.04M | 69.25M | 391.83M | 289.76M |
| Gross Profit | 234.20M | 72.22M | 0 | 0 | 303.42M | 218.16M |
| EBITDA | -806.45M | -909.45M | -817.88M | -888.76M | -426.17M | -357.88M |
| Net Income | -808.44M | -916.25M | -756.45M | -854.15M | -331.83M | -301.17M |
Balance Sheet | ||||||
| Total Assets | 2.00B | 2.08B | 2.76B | 2.62B | 3.21B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 1.70B | 1.62B | 2.31B | 2.14B | 2.76B | 2.14B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 744.51M | 770.11M | 648.92M | 596.95M | 419.50M | 129.48M |
| Stockholders Equity | 1.25B | 1.31B | 2.11B | 2.02B | 2.79B | 2.51B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 0 | -661.17M | -689.10M | 15.80M | -560.92M |
| Operating Cash Flow | -755.78M | -755.78M | -661.17M | -689.10M | 15.80M | -560.92M |
| Investing Cash Flow | -154.01M | -154.01M | -121.36M | -120.88M | -254.38M | 0 |
| Financing Cash Flow | 84.14M | 84.14M | 838.23M | 69.16M | 603.11M | 595.90M |
Kringle Pharma, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4884, the sentiment is Neutral. The current price of 519.00 is below the 20-day moving average (MA) of 566.05, below the 50-day MA of 523.18, and above the 200-day MA of 423.44, indicating a neutral trend. The MACD of -8.71 indicates Positive momentum. The RSI at 45.36 is Neutral, neither overbought nor oversold. The STOCH value of 47.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4884.
Kringle Pharma, Inc. Peers Comparison
Overall Rating
- JP:488456Neutral
JP:458752Neutral
JP:459142Neutral
JP:459842Neutral
JP:457141Neutral
JP:488138Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4884 | 56Neutral | JPY 4.48B | -4.69 | ― | ― | 513.34% | 20.92% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4587 | 52Neutral | JPY 139.56B | -38.46 | -7.17% | ― | 14.25% | 50.07% |
| JP:4591 | 42Neutral | JPY 3.31B | -2.49 | ― | ― | ― | 9.55% |
| JP:4598 | 42Neutral | JPY 1.29B | -0.44 | ― | ― | ― | 20.94% |
| JP:4571 | 41Neutral | JPY 6.56B | -5.20 | -33.61% | ― | 74.24% | -7.78% |
| JP:4881 | 38Underperform | JPY 2.08B | -1.08 | ― | ― | -27.93% | 22.36% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4884 | Kringle Pharma, Inc. | 519.00 | 91.00 | 21.26% | |
| JP:4587 | Peptidream | 1081.00 | -550.00 | -33.72% | |
| JP:4571 | NanoCarrier Co., Ltd. | 70.00 | -88.00 | -55.70% | |
| JP:4591 | Ribomic, Inc. | 57.00 | -31.00 | -35.23% | |
| JP:4598 | Delta-Fly Pharma, Inc. | 60.00 | -452.00 | -88.28% | |
| JP:4881 | FunPep Company Limited | 41.00 | -50.00 | -54.95% |
Kringle Pharma, Inc. Corporate Events
Kringle Pharma Seeks U.S. Phase 3 Trial for Spinal Cord Injury Drug
Kringle Pharma has submitted an Investigational New Drug application to the U.S. FDA seeking to initiate a Phase 3 clinical trial of oremepermin alfa, a recombinant human hepatocyte growth factor, for the treatment of acute spinal cord injury in the...
Kringle Pharma Boosts Sales but Warns of Deeper Full-Year Losses
Kringle Pharma reported a sharp rise in net sales to ¥323 million for the nine months ended June 30, 2026, up more than fivefold year on year, but continued to post operating and net losses, with a nine-month loss of ¥631 million and a basic loss per...
Kringle Pharma Launches Additional Phase 3 Trial of Oremepermin Alfa in Acute Spinal Cord Injury
Kringle Pharma has launched an additional Phase 3 trial in Japan to evaluate oremepermin alfa, a recombinant human hepatocyte growth factor, in patients with acute cervical spinal cord injury. The multicenter, open-label study will enroll 10 adults w...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026